Valneva SE Share Price & Technical Analysis
VALN · $5.93 (+1.02%)
Healthcare / Biotechnology
$5.93
+1.02%
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile to…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
9% return in May, 12% avg return in past 3 year May month.
-27% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 3% | 21% | -43% | -18% | 9% | – | – | – | – | – | – | – | -27% |
| 25 | 23% | 19% | -3% | -9% | 2% | -11% | 24% | 22% | 51% | -24% | 2% | -3% | 93% |
| 24 | -20% | -10% | 16% | -5% | 17% | -24% | -1% | 1% | -18% | -5% | -29% | 10% | -68% |
| 23 | -5% | -15% | -13% | -10% | 18% | 29% | 0% | -6% | -17% | 0% | 4% | -10% | -26% |
| 22 | -36% | -7% | 0% | -26% | -2% | -8% | -5% | -7% | -44% | 28% | -7% | -7% | -120% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$559.46M
P/E ratio
—
52W high
$12.25
52W low
$5.06
Volume
75,713
Beta
1.33
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Valneva SE share price today?
- Valneva SE (VALN) last traded around $5.93 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VALN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VALN. Download the app for real-time alerts.
- How can I analyze Valneva SE stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.